FINWIRES · TerminalLIVE
FINWIRES

SSY Group Unit Enters Talks Over Dialysis Drug

By

SSY Group (HKG:2005) said its Shijiazhuang No. 4 Pharmaceutical unit is negotiating an exclusive license for peritoneal dialysis treatment OPT101, according to a Monday filing with the Hong Kong bourse.

The firm signed a letter of intent with the drug's developer, Opterion Health, for a possible license covering China that would expire in 2038. The SSY Group unit will also receive priority over licenses covering Hong Kong, Taiwan, and Russia.

A formal agreement is expected in the third quarter of 2026, SSY Group said.

Shares of SSY gained over 1% in recent trade.

Related Articles

Asia

Singapore Regulator to Streamline 'Single Family Office' Framework

The Monetary Authority of Singapore has revised its "single family office" (SFOs) framework to streamline the process for SFOs to establish operations in Singapore, according to a MAS release.An SFO in Singapore is a privately held corporate entity set up by one "ultra-high-net-worth" family to manage assets, investments, and wealth of a single family.The registration protocols have been simplified, effective June 15, with offices required to notify MAS of their operations through a MAS-licensed bank.Annual reporting has been made more straightforward for SFOs, with information on total assets under management and the name of its bank.

$^STI
Asia

Klevo Rewards Plans Stablecoin Trial Launch by June 30; Shares Fall 4%

Klevo Rewards (ASX:KLV) said it plans to launch a trial of its KLVAUD Australian dollar-backed stablecoin by June 30, according to a Monday filing with the Australian bourse.The company's Fly Wallet subsidiary received legal advice indicating that the stablecoin may qualify as an eligible stablecoin under the current regulatory framework, subject to conditions, per the filing.KLVAUD is planned to be fully backed one-to-one by Australian dollars held in segregated reserve accounts, and aims to support Fly Wallet's broader payments system, the company said.Klevo Rewards shares fell 4% in recent Monday trade.

$ASX:KLV
Asia

Bio-Thera Solutions Gets Europe's Results on On-Site Inspection

Bio-Thera Solutions (SHA:688177) received the results of the European Union's inspection of its Yonghe manufacturing facility, according to a Shanghai bourse filing on Monday.The French National Agency for the Safety of Medicines and Health Products conducted an inspection on the site between Feb. 4 and Feb. 12.The European Medicines Agency handed a GMP or good manufacturing practice certificate to the company after the factory's drug substance operations passed regulatory standards. However, the regulator found deficiencies in the deviation management measures for the finished formulation of the drugs.

$SHA:688177